Our Science

Posters & Presentations

IDWeek 2024

October 16 – October 19, 2024

Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax

Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax

Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial

Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial

Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial

Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial

ASM Microbe 2024

June 13 – June 17, 2024

In Vitro Assessment of Sulopenem against Mycobacterium avium Complex

In Vitro Assessment of Sulopenem against Mycobacterium avium Complex

ID Week 2023

October 11 – October 15, 2023

Desirability of outcome ranking (DOOR): application to a phase 3 registrational trial evaluating sulopenem for patients with complicated intra-abdominal infection (cIAI)

Desirability of outcome ranking (DOOR): application to a phase 3 registrational trial evaluating sulopenem for patients with complicated intra-abdominal infection (cIAI)

Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model

Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model

Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model

Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model

ASM Microbe 2023

June 15 – June 19, 2023

β-lactamase characterization of baseline Enterobacterales pathogens from a Phase 3 trial of sulopenem for the treatment of uncomplicated urinary tract infection

β-lactamase characterization of baseline Enterobacterales pathogens from a Phase 3 trial of sulopenem for the treatment of uncomplicated urinary tract infection

β-lactamase characterization of baseline Enterobacterales pathogens from a Phase 3 trial of sulopenem for the treatment of complicated urinary tract infection

β-lactamase characterization of baseline Enterobacterales pathogens from a Phase 3 trial of sulopenem for the treatment of complicated urinary tract infection

β-lactamase characterization of baseline Enterobacterales pathogens from a Phase 3 trial of sulopenem for the treatment of complicated intraabdominal infection

β-lactamase characterization of baseline Enterobacterales pathogens from a Phase 3 trial of sulopenem for the treatment of complicated intraabdominal infection

ECCMID 2023

April 15 – April 18, 2023

Desirability of outcome ranking (DOOR): application to a phase 3 registrational trial evaluating sulopenem for patients with complicated urinary tract infection (cUTI)

Desirability of outcome ranking (DOOR): application to a phase 3 registrational trial evaluating sulopenem for patients with complicated urinary tract infection (cUTI)

Desirability of outcome ranking (DOOR): application to a phase 3 registrational trial evaluating sulopenem for patients with uncomplicated urinary tract infection (uUTI)

Desirability of outcome ranking (DOOR): application to a phase 3 registrational trial evaluating sulopenem for patients with uncomplicated urinary tract infection (uUTI)

ID Week 2022

October 19 – October 23, 2022

Murine Efficacy Studies of Sulopenem Against Bacillus anthracis

Murine Efficacy Studies of Sulopenem Against Bacillus anthracis

Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection

Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection

ASM Microbe 2022

June 9 – June 13, 2022

In Vitro Activity of Sulopenem and Comparative Agents against Bacterial Pathogens Isolated from Canadian Patients with Urinary Tract Infections: CANWARD Surveillance Study 2014-2021

In Vitro Activity of Sulopenem and Comparative Agents against Bacterial Pathogens Isolated from Canadian Patients with Urinary Tract Infections: CANWARD Surveillance Study 2014-2021

ECCMID 2022

April 23 – April 26, 2022

In Vitro Activity of Sulopenem and Comparator Agents Against Anaerobic Clinical Isolates from the SENTRY Surveillance Program 2018-2020

In Vitro Activity of Sulopenem and Comparator Agents Against Anaerobic Clinical Isolates from the SENTRY Surveillance Program 2018-2020

Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem Etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin and Metronidazole or Amoxicillin-Clavulanate in the Treatment of Complicated Intraabdominal Infections: The SURE-3 Trial

Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem Etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin and Metronidazole or Amoxicillin-Clavulanate in the Treatment of Complicated Intraabdominal Infections: The SURE-3 Trial

ID Week 2021

September 29 – October 3, 2021

In Vitro Antibacterial Susceptibility Testing of Sulopenem Against Category A and B Bio-Threat Bacterial Pathogens

In Vitro Antibacterial Susceptibility Testing of Sulopenem Against Category A and B Bio-Threat Bacterial Pathogens

World Microbe Forum

June 20 – June 24, 2021

Zhanel, et al. In vitro activity of Sulopenem and comparative agents against UTI isolates. CANWARD 2014-2020

Zhanel, et al. In vitro activity of Sulopenem and comparative agents against UTI isolates. CANWARD 2014-2020

ID Week 2020

October 21, 2020

Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial

Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial

Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/ Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial

Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/ Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial

ASM Microbe 2020

June 18 – June 22, 2020

Extended Spectrum β-lactamase Non-susceptibility Is Increasing Over Time In Patients Hospitalized With Culture Positive Urinary Enterobacterales

Extended Spectrum β-lactamase Non-susceptibility Is Increasing Over Time In Patients Hospitalized With Culture Positive Urinary Enterobacterales

A Phase 1 Study Of The Effects Of Itraconazole On The Pharmacokinetics Of Oral And IV Sulopenem In Healthy Adult Subjects

A Phase 1 Study Of The Effects Of Itraconazole On The Pharmacokinetics Of Oral And IV Sulopenem In Healthy Adult Subjects

Surveillance Of Sulopenem And Comparator Agents Against Recent (2019) Enterobacterales Isolates From The United States

Surveillance Of Sulopenem And Comparator Agents Against Recent (2019) Enterobacterales Isolates From The United States

ASM Microbe 2019

June 20 – June 24, 2019

Aronin et al. - Impact of Urine Analysis Methods in the Diagnosis of Uncomplicated Urinary Tract Infection

Aronin et al. - Impact of Urine Analysis Methods in the Diagnosis of Uncomplicated Urinary Tract Infection

Dunne et al. - Failure of Empiric Treatment of Uncomplicated Urinary Tract Infection (UTI) Associated with Resistant Pathogens

Dunne et al. - Failure of Empiric Treatment of Uncomplicated Urinary Tract Infection (UTI) Associated with Resistant Pathogens

Dunne et al. - Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Adult Women

Dunne et al. - Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Adult Women

ECCMID 2019

April 15, 2019

Dunne et al. - Post-Antibiotic and Sub-Inhibitory Minimum Inhibitory Concentration Effects of Sulopenem

Dunne et al. - Post-Antibiotic and Sub-Inhibitory Minimum Inhibitory Concentration Effects of Sulopenem

Dunne et al. - In vitro activity of Sulopenem Against Resistant Neisseria gonorrhoeae

Dunne et al. - In vitro activity of Sulopenem Against Resistant Neisseria gonorrhoeae

Dunne et al. - A patient-specific clinical predictive model to anticipate the risk of treatment failure in uncomplicated urinary tract infections

Dunne et al. - A patient-specific clinical predictive model to anticipate the risk of treatment failure in uncomplicated urinary tract infections

ID Week 2018

October 3 – October 7, 2018

Dunne et al. - A Phase 1, Randomized, Open-label, Crossover Study In Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem

Dunne et al. - A Phase 1, Randomized, Open-label, Crossover Study In Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem

Puttagunta et al. - Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection

Puttagunta et al. - Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection

Dunne et al. - The prevalence of Enterobacteriaceae resistant to all major classes of oral antibiotics from outpatient urine cultures in the United States and effect on clinical outcomes

Dunne et al. - The prevalence of Enterobacteriaceae resistant to all major classes of oral antibiotics from outpatient urine cultures in the United States and effect on clinical outcomes

ASM Microbe 2018

June 7 – June 11, 2018

Dunne et al. - Prediction of Sulopenem Activity Against Enterobacteriaceae Using Ertapenem as a Surrogate

Dunne et al. - Prediction of Sulopenem Activity Against Enterobacteriaceae Using Ertapenem as a Surrogate

Puttagunta et al. - Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Uncomplicated Urinary Tract Infection Due to Fluoroquinolone Non-susceptible Enterobacteriaceae

Puttagunta et al. - Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Uncomplicated Urinary Tract Infection Due to Fluoroquinolone Non-susceptible Enterobacteriaceae

Aronin et al. - Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection

Aronin et al. - Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection

Zhanel et al. - In Vitro Activity of Sulopenem, An Oral Penem, against Escherichia coli Isolated from Urine Specimens of Patients Across Canada in 2014-2016

Zhanel et al. - In Vitro Activity of Sulopenem, An Oral Penem, against Escherichia coli Isolated from Urine Specimens of Patients Across Canada in 2014-2016

ECCMID 2018

April 21 – April 24, 2018

Dunne et al. - Antimicrobial Activity of Sulopenem in the Urine of Healthy Volunteers

Dunne et al. - Antimicrobial Activity of Sulopenem in the Urine of Healthy Volunteers

Dunne et al. - Impact of ESBL-positivity and Quinolone Non-Susceptibility on Outcome for Inpatients with Complicated Urinary Tract Infection: A Multicenter Evaluation in the U.S.

Dunne et al. - Impact of ESBL-positivity and Quinolone Non-Susceptibility on Outcome for Inpatients with Complicated Urinary Tract Infection: A Multicenter Evaluation in the U.S.

Puttagunta et al. -Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Uncomplicated Urinary Tract Infection Due to Antibiotic Non-susceptible Enterobacteriaceae

Puttagunta et al. -Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Uncomplicated Urinary Tract Infection Due to Antibiotic Non-susceptible Enterobacteriaceae

ID Week 2017

October 4 – October 8, 2017

Puttagunta et al. – Prevalence of Extended Spectrum Beta-Lactamase Producing and Quinolone Non-susceptible Enterobacteriaceae in Inpatient and Outpatient Settings in the USA from 2011-2017

Puttagunta et al. – Prevalence of Extended Spectrum Beta-Lactamase Producing and Quinolone Non-susceptible Enterobacteriaceae in Inpatient and Outpatient Settings in the USA from 2011-2017

Dunne et al. – A Phase 1 Study to Assess the Pharmacokinetics of Sulopenem Etzadroxil (PF-03709270)

Dunne et al. – A Phase 1 Study to Assess the Pharmacokinetics of Sulopenem Etzadroxil (PF-03709270)

ASM Microbe 2017

June 1 – June 5, 2017

Puttagunta et al. – Antimicrobial Activity of Sulopenem Tested against Gram-positive and Gram-negative Organisms from the United States and Europe (2013-2015)

Puttagunta et al. – Antimicrobial Activity of Sulopenem Tested against Gram-positive and Gram-negative Organisms from the United States and Europe (2013-2015)

ICAAC/IDSA Week 2008

October 25 – October 28, 2008

PHARMACOKINETICS (PK), SAFETY AND TOLERABILITY OF SINGLE ORAL DOSES OF PF-03709270, WITH AND WITHOUT CO-ADMINISTRATION OF PROBENECID

PHARMACOKINETICS (PK), SAFETY AND TOLERABILITY OF SINGLE ORAL DOSES OF PF-03709270, WITH AND WITHOUT CO-ADMINISTRATION OF PROBENECID